In this edition, FDA approves Rybrevant for advanced lung cancer, screening orders in eligible patients higher with digital health program and more. Read the full coverage here: FDA approves Rybrevant for advanced lung cancer Lung cancer screening orders in eligible patients higher with digital health program FDA approves Opdivo regimen for resectable NSCLC Study quantifies survival benefit of immunotherapy in metastatic NSCLC FDA expands osimertinib approval for advanced non-small cell lung cancer References: Miller DP, et al. A direct-to-patient digital health program increases lung cancer screening: A pragmatic randomized controlled trial of mPATH-Lung. Presented at: CHEST Annual Meeting; Oct. 6-9, 2024; Boston. Press Release Press Release Press Release Ward Y, et al. Cancer. 2024;doi:10.1002/cncr.35476.

Ver todos los episodios